Nephrotic Syndrome Diagnostics & Therapeutics Market
Global Nephrotic Syndrome Diagnostics & Therapeutics Market Size, Share & Trends Analysis Report by Diagnosis Tests (Urinalysis, Blood Tests, Kidney Biopsy, and Others) By Treatment (Blood Pressure Lowering Medications, Immune System-Suppressing Medications, Cholesterol-Reducing Medications, and Others) Forecast 2021-2027
The global nephrotic syndrome diagnostics & therapeutics market is anticipated to grow at a CAGR of 5.6% during the forecast period. Nephrotic syndrome is a kidney disease in which the body excretes an excessive amount of protein in the urine. Damage to the clusters of tiny blood vessels in kidneys that remove waste and excess water from blood is the most common cause of the nephrotic syndrome. Diabetes, which can cause diabetic nephropathy and thus affect glomeruli, has been one of the major factors driving the market growth during the forecast period. The other factors being the increasing rate of hyperlipidemia, the rise of complications, such as thromboembolism, HIV, hepatitis B, and hepatitis C, also contribute to the rising rate of nephrotic syndrome incidence and prevalence across the globe will further driving the growth of the market. Several factors, such as the absence of reimbursement policies in both low- and middle-income countries, serve as a significant restraint on the demand for nephrotic syndrome diagnostics and therapeutics. The high cost of a kidney transplant and dialysis treatment also has an impact on market growth. Moreover, pipeline drugs for nephrotic syndrome would drive the demand creating opportunities for the growth of the market.
Segmental Outlook
The global nephrotic syndrome diagnostics & therapeutics market is segmented based on diagnostic tests and treatment. Based on diagnosis tests, the market is segmented into urinalysis, blood tests, kidney biopsy, and others. Further on the basis of treatment, the market is segmented into blood pressure-lowering medications, immune system-suppressing medications, cholesterol-reducing medications, and others.
Global Nephrotic Syndrome Diagnostics & Therapeutics Market Share by Diagnostics Tests, 2020 (%)
Urinalysis is estimated to be the fastest-growing segment in the global Nephrotic Syndrome Diagnostics & Therapeutics Market
Among diagnosis tests, urinalysis is projected to grow significantly during the forecast period. Urinalysis is a series of tests that can detect a variety of diseases. It may be used to test for and/or diagnose a variety of diseases, including urinary tract infections, kidney disorders, liver complications, diabetes, and other metabolic disorders and others. Additionally, Urinalysis may be used in combination with other tests, such as urine albumin, to monitor treatment in people with diseases or disorders like kidney disease or diabetes. A urinalysis is just one piece of data about what's going on inside the body. The test can reveal warning signs, but it can't guarantee that something is wrong with the body. The results could indicate that the body needs additional testing and follow-up. Therefore the urinalysis is widely adopted for the diagnosis of nephrotic syndrome and further contribute to the growth of the market.
Regional Outlooks
The global nephrotic syndrome diagnostics & therapeutics market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to have a significant share in the global market attributed to increasing healthcare expenditures and a high level of public awareness related to the diagnosis and treatment of the nephrotic syndrome. Furthermore, the market is also driven by advances in novel drug development for this disease in the field.
Global Nephrotic Syndrome Diagnostics & Therapeutics Market Growth, by Region 2021-2027
Asia-Pacific is expected to grow significantly in the global nephrotic syndrome diagnostics & therapeutics market during the forecast period.
Asia-Pacific projected to have significant growth in the nephrotic syndrome diagnostics & therapeutics market. The growth is attributed due to an increase in the number of diabetic patients and rising per capita income as a result there are increases in healthcare spending. As diabetes is the one major reason for the growing nephrotic syndrome in the region, according to American Diabetes Association, between 2000 and 2035, type 2 diabetes is expected to increase by more than 150 % in South Asia. More than 60% of diabetics live in Asia, with China and India accounting for nearly half of all cases. Diabetes affects more than 138.2 million people in the Western Pacific, the world's most populated country, with the number expected to increase to 201.8 million by 2035.
Market Players Outlook
The key players of the nephrotic syndrome diagnostics & therapeutics market include Abbott Laboratories, Asahi Kasei Pharma Corp., Bristol-Myers Squibb Co., GlaxoSmithKline PLC, Pfizer, Inc., Eli Lilly and Co., Novartis International AG and others. The market players are considerably contributing to the market growth by adopting various strategies including mergers, and acquisitions, collaborations, and new product launches, to stay competitive in the market. For instance, in April 2019, to investigate ANG-3070, Angion has partnered with the Nephrotic Syndrome Study Network (NEPTUNE), an interconnected consortium of academic medical centres, patient care groups, and clinical research services committed to improving the understanding and treatment of kidney disorders.
The Report Covers
- Market value data analysis of 2020 and forecast to 2027.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Nephrotic Syndrome Diagnostics & Therapeutics market
- Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying 'who-stands-where in the market.
1. Report Summary
1.1. Research Methods and Tools
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Nephrotic Syndrome Diagnostics & TherapeuticsIndustry
• Recovery Scenario of Global Nephrotic Syndrome Diagnostics & Therapeutics Industry
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Regulations
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on key players
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Nephrotic Syndrome Diagnostics & Therapeutics market By Diagnosis Tests
5.1.1. Urinalysis
5.1.2. Blood Tests
5.1.3. Kidney Biopsy
5.1.4. Others (CT Scan, Renal Ultra-Sonography)
5.2. Global Nephrotic Syndrome Diagnostics & Therapeutics market by Treatment
5.2.1. Blood Pressure Lowering Medications
5.2.1.1. Angiotensin-Converting Enzyme (ACE) Inhibitors
5.2.1.2. Angiotensin Receptor Blockers (ARBs)
5.2.1.3. Others (Renin Inhibitors and Benazepril)
5.2.2. Immune System-Suppressing Medications
5.2.3. Cholesterol-Reducing Medications
5.2.4. Others (Blood Thinners)
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. South Korea
6.3.5. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Abbott Laboratories
7.2. Asahi Kasei Pharma Corp.
7.3. AstraZeneca PLC
7.4. Aurinia Pharmaceuticals Inc.
7.5. Bristol-Myers Squibb Co.
7.6. DaVita Inc.
7.7. Eli Lilly and Co.
7.8. GeneDx Inc.
7.9. GlaxoSmithKline PLC
7.10. Johnson and Johnson Services Inc.
7.11. Mallinckrodt LLC
7.12. Novartis International AG
7.13. Pfizer Inc.
7.14. Sanofi SA
7.15. ZyVersa Therapeutics, Inc.
1. GLOBAL NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS TESTS, 2020-2027 ($ MILLION)
2. GLOBAL URINALYSIS FOR NEPHROTIC SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
3. GLOBAL BLOOD TESTS FOR NEPHROTIC SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
4. GLOBAL KIDNEY BIOPSY FOR NEPHROTIC SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
5. GLOBAL OTHER DIAGNOSTOCS TEST FOR NEPHROTIC SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
6. GLOBAL NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT,2020-2027 ($ MILLION)
7. GLOBAL BLOOD PRESSURE LOWERING MEDICATIONS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
8. GLOBAL IMMUNE SYSTEM-SUPPRESSING MEDICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
9. GLOBAL CHOLESTEROL-REDUCING MEDICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
10. GLOBAL OTHER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
11. GLOBAL NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
12. NORTH AMERICAN NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
13. NORTH AMERICAN NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS TESTS,2020-2027 ($ MILLION)
14. NORTH AMERICAN NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT,2020-2027 ($ MILLION)
15. EUROPEAN NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
16. EUROPEAN NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS TESTS,2020-2027 ($ MILLION)
17. EUROPEAN NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
18. ASIA-PACIFIC NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
19. ASIA-PACIFIC NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS TESTS,2020-2027 ($ MILLION)
20. ASIA-PACIFIC NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
21. REST OF THE WORLD NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
22. REST OF THE WORLD NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS TESTS 2020-2027 ($ MILLION)
23. REST OF THE WORLD NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET, 2020-2027 (% MILLION)
2. IMPACT OF COVID-19 ON GLOBAL NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET BY SEGMENT, 2020-2027 (% MILLION)
3. RECOVERY OF GLOBAL NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET, 2020-2027 (%)
4. GLOBAL NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET SHARE BY DIAGNOSIS TESTS,2020 VS 2027 (%)
5. GLOBAL NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET SHARE BY TREATMENT, 2020 VS 2027 (%)
6. GLOBAL NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
7. GLOBAL URINALYSIS FOR NEPHROTIC SYNDROME DIAGNOSTICS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
8. GLOBAL BLOOD TESTS FOR NEPHROTIC SYNDROME DIAGNOSTICS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
9. GLOBAL KIDNEY BIOPSYNEPHROTIC SYNDROME DIAGNOSTICS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
10. GLOBAL BLOOD PRESSURE LOWERING MEDICATIONS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
11. GLOBAL IMMUNE SYSTEM-SUPPRESSING MEDICATIONS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
12. GLOBAL CHOLESTEROL-REDUCING MEDICATIONS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
13. GLOBAL OTHER NEPHROTIC SYNDROME TREATMENT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
14. US NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2020-2027($ MILLION)
15. CANADA NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2020-2027($ MILLION)
16. UK NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS AND BLOOD TESTS MARKET SIZE, 2020-2027($ MILLION)
17. FRANCE NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2020-2027($ MILLION)
18. GERMANY NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2020-2027($ MILLION)
19. ITALY NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2020-2027($ MILLION)
20. SPAIN NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2020-2027($ MILLION)
21. REST OF EUROPE NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2020-2027($ MILLION)
22. INDIA NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2020-2027($ MILLION)
23. CHINA NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2020-2027($ MILLION)
24. JAPAN NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2020-2027($ MILLION)
25. SOUTH KOREA NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2020-2027($ MILLION)
26. REST OF ASIA-PACIFIC NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2020-2027($ MILLION)
27. REST OF THE WORLD NEPHROTIC SYNDROME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2020-2027($ MILLION)
